Abstract: Objective To assess the in vivo toxicity of a novel chordoma diagnostic agent in animal models in order to provide data for subsequent investigation into novel diagnostic and treatment strategies for chordoma. Methods Forty-eight male and female C57 mice were randomly assigned to four groups: a high-dose (2 mg·kg^-1) group, therapeutic-dose (0.4 mg·kg^-1) group, and low-dose (0.08 mg·kg^-1) group before being administered with a novel diagnostic agent via tail-vein injection or local infusion through a skin incision. These mice were observed daily for 14 consecutive days while their survival, body-weight changes, and abnormal behavior were recorded. At the end of observation, these mice were sacrificed according to approved protocols before their liver, kidney, heart, lung, spleen, and other key organs were harvested for paraffin sections, HE staining and pathological changes. Results During the 14-day experiment, no mortality or abnormal behavior was observed in mice in any group, suggesting that the novel diagnostic agent as used here had no obvious toxic effects on mice. A comparison of body weight between the treatment groups and the control group found no statistically significant differences in the pattern of weight gain curves (P<0.05). Paraffin-embedded tissue sections showed no characteristic pathological changes in any of the groups. Conclusion The novel diagnostic agent induces no pronounced acute manifestations within the dose range and period established in this study.

Key words: Central Nervous System Disease, Chordoma, Diagnostic Agent, In vivo Toxicity, Mice